Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
J Control Release. 2010 Mar 19;142(3):416-21. doi: 10.1016/j.jconrel.2009.11.008. Epub 2009 Nov 15.
A lipid coated calcium phosphate (LCP) nanoparticle (NP) formulation was developed for efficient delivery of small interfering RNA (siRNA) to a xenograft tumor model by intravenous administration. Based on the previous formulation, liposome-polycation-DNA (LPD), which was a DNA-protamine complex wrapped by cationic liposome followed by post-insertion of PEG, LCP was similar to LPD NP except that the core was replaced by a biodegradable nano-sized calcium phosphate precipitate prepared by using water-in-oil micro-emulsions in which siRNA was entrapped. We hypothesized that after entering the cells, LCP would de-assemble at low pH in the endosome, which would cause endosome swelling and bursting to release the entrapped siRNA. Such a mechanism was demonstrated by the increase of intracellular Ca(2+) concentration as shown by using a calcium specific dye Fura-2. The LCP NP was further modified by post-insertion of polyethylene glycol (PEG) with or without anisamide, a sigma-1 receptor ligand for systemic administration. Luciferase siRNA was used to evaluate the gene silencing effect in H-460 cells which were stably transduced with a luciferase gene. The anisamide modified LCP NP silenced about 70% and 50% of luciferase activity for the tumor cells in culture and those grown in a xenograft model, respectively. The untargeted NP showed a very low silencing effect. The new formulation improved the in vitro silencing effect 3-4 folds compared to the previous LPD formulation, but had a negligible immunotoxicity.
一种脂质包覆的磷酸钙 (LCP) 纳米颗粒 (NP) 制剂被开发用于通过静脉注射将小干扰 RNA (siRNA) 高效递送至异种移植肿瘤模型。基于先前的制剂,即被阳离子脂质体包裹的 DNA-聚阳离子复合物,随后插入 PEG,LCP 类似于 LPD NP,只是核心被由水包油微乳液制备的可生物降解的纳米级磷酸钙沉淀物所取代,其中包裹了 siRNA。我们假设,进入细胞后,LCP 会在内体中低 pH 下解组装,导致内体肿胀和破裂,从而释放包裹的 siRNA。通过使用钙特异性染料 Fura-2 显示细胞内 Ca(2+) 浓度增加,证明了这种机制。LCP NP 进一步通过插入聚乙二醇 (PEG) 进行修饰,无论是否插入具有 sigma-1 受体配体的anisamide,以进行系统给药。荧光素酶 siRNA 用于评估稳定转染荧光素酶基因的 H-460 细胞中的基因沉默效果。anisamide 修饰的 LCP NP 对培养中的肿瘤细胞和异种移植模型中生长的肿瘤细胞的荧光素酶活性分别沉默了约 70%和 50%。未靶向的 NP 表现出非常低的沉默效果。与先前的 LPD 制剂相比,新制剂将体外沉默效果提高了 3-4 倍,但免疫毒性可忽略不计。